## ROP: Roper Technologies, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_20 -1.8% below STRENGTH zone (4.0-10.0%); PEG 2.59 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($431.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Roper Technologies (ROP): Evaluating Valuation After Post‑Earnings Pullback and Increased Insider Buying**
- Source: Simply Wall Street | 20251208T022541 | Somewhat-Bullish | Relevance: 99%
-  Roper Technologies (ROP) has experienced a post-earnings slide, making its valuation more attractive given its high-margin, recurring revenue model. Insider buying signals management's confidence, and the stock now trades at a discount to analyst targets and intrinsic value estimates. Despite a recent weak performance, the company's revenue and earnings are growing, presenting a potential buying opportunity.

**2. Roper Technologies (ROP): Evaluating Valuation After Post‑Earnings Pullback and Increased Insider Buying**
- Source: Simply Wall Street | 20251208T050841 | Somewhat-Bullish | Relevance: 99%
- Roper Technologies (ROP) has become more appealing after its post-earnings decline, with its stock price now reflecting its high margin, recurring revenue model, and increased insider buying signaling management's confidence. Despite recent negative share price performance, the company's healthy revenue and earnings growth suggest it might be an undervalued buying opportunity, especially as it trades at a significant discount to analyst targets and intrinsic value estimates. However, potential risks like integration missteps or AI-enabled competition could affect its premium valuation.

**3. Responsive Playbooks and the ROP Inflection**
- Source: news.stocktradersdaily.com | 20251207T091022 | Neutral | Relevance: 98%
- This article analyzes Roper Technologies Inc. (NYSE: ROP), highlighting neutral readings in shorter horizons that could indicate an easing of a long-term weak bias, although no clear price positioning signal has been identified. It details AI-generated trading strategies including a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, alongside multi-timeframe signal analysis. The piece also notes elevated downside risk due to the absence of additional long-term support signals.

**4. Roper Technologies completes $2 billion senior notes offering**
- Source: Investing.com | 20251208T114200 | Somewhat-Bullish | Relevance: 98%
- Roper Technologies has completed a $2 billion offering of senior unsecured notes, comprising three tranches due in 2028, 2030, and 2035. This financing follows other recent company activities, including a raised stock price target by RBC Capital and strategic acquisitions by its subsidiaries. The move enhances the financial position of the prominent software industry player.

**5. Cellebrite DI (CLBT) Is Up 8.1% After Q3 Beat And Corellium Deal - What's Changed**
- Source: Simply Wall Street | 20251206T035204 | Neutral | Relevance: 61%
- Cellebrite DI (CLBT) recently exceeded Q3 expectations, driven by strong execution, demand for its digital investigation platforms, and the rapid growth of its Guardian solution. The acquisition of Corellium for US$170 million enhances Cellebrite's AI-powered investigation capabilities, broadening its potential use across defense, intelligence, and enterprise sectors. Despite contract delays in the U.S. federal segment, the Q3 performance and the Corellium deal suggest a positive shift in Cellebrite's investment narrative and long-term outlook.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $475 | $506 | -6% |
| 2025-11-20 | Piper Sandler | $600 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Underweight |
| 2025-11-20 | Piper Sandler | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($4.16M) |
| Sells | 2 ($8.94M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+1.8%)
- Blackrock Inc.: 8.6% (-2.1%)
- State Street Corpora: 4.7% (+0.9%)
- Morgan Stanley: 3.7% (+6.8%)
- JPMORGAN CHASE & CO: 3.0% (+225.1%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Long-term trend broken: trading 16.3% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.59 signals overvaluation risk, limited margin of safety. Forward P/E 20.7x stretched relative to 8% growth. Quality metrics strong (margin 20%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.1B |
| Beta | 0.94 |
| 52W Range | $435.42 - $595.17 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.59 |
| Forward P/E | 20.7 |
| Current P/E | 22.4 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.8% (minimal 5-day change). Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.84x), long-term trend not supportive. MACD histogram positive (2.24), confirming momentum. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.82% (CS: 41) | Neutral |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | 2.24 | Bullish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 0.951x | Below |
| vs SMA200 | 0.837x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $446.71
- **Stop Loss:** $431.91 (3.3% risk)
- **Target:** $461.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $36,183.51
- **Portfolio %:** 36.18%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

### Earnings

**Next:** 2026-01-29 (Est: $5.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.11 | $5.14 | +0.6% |
| 2025Q2 | $4.83 | $4.87 | +0.8% |
| 2025Q1 | $4.74 | $4.78 | +0.8% |
| 2024Q4 | $4.73 | $4.81 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*